Posts tagged with "Merck"

Mina Tocalini, 360 Magazine, COVID-19

Annual (RED) Shopathon Lights Up Today

The sixth annual (RED) Shopathon lights up today ahead of World AIDS Day and Giving Tuesday, December 1st. Offering more than 200 stylish and giftable products that give back with every purchase, the campaign is supported by Merck (known as MSD outside the U.S. and Canada) and will see (RED) generate money for the Global Fund to fight two pandemics: AIDS and COVID-19.

THE ALL-NEW (echo)RED AND OVER 170+ (RED) PRODUCTS ON AMAZON.COM/RED:

For the fourth year, (RED) is partnering with Amazon to give customers a single destination to shop more than 170 products that give back, spanning tech, health & wellness, kitchen & home, and more.

New for 2020 is the next-generation, limited-edition (echo)RED, featuring an all-new sleek spherical design, premium sound, and smart home hub support for Zigbee, Bluetooth Low Energy, and Amazon Sidewalk. Amazon will donate $10 of every (echo)RED sale to the Fund for the Global Fund to support COVID-19 response and HIV/AIDS programs in sub-Saharan Africa.

Customers can also donate to (RED)’s fight against these two pandemics on any Alexa-enabled device by simply saying, “Alexa, donate to (RED).” With all products available at amazon.com/red, shoppers can put impact into every purchase. The limited-edition (echo)RED is available starting today for only $99.99 (amazon.com/echored).

(RED) LAUNCHES ITS FIRST-EVER VIRTUAL POP-UP SHOP ON SNAPCHAT:

(RED) is launching its first-ever immersive pop-up shop on Snapchat. Using Snapchat’s AR technology, users can now browse and buy Amazon.com/RED products directly from their mobile app, and support (RED)’s fight against AIDS and COVID-19. The lens, supported by Merck (known as MSD outside the U.S. and Canada), is live worldwide today and accessible throughout the duration of the campaign. Snap, shop, and save lives by going to this link.

Dragonfly x Merck

Dragonfly Therapeutics, Inc. (“Dragonfly”), today announced a strategic collaboration with Merck, known as MSD outside the United States and Canada, through a subsidiary, to discover, develop and commercialize innovative immunotherapies for patients with solid tumor cancers. The collaboration grants Merck the option to license exclusive worldwide intellectual property rights to products developed using Dragonfly’s TriNKET™ technology platform for a number of solid-tumor programs, with the potential to earn Dragonfly up to $695 million in up front and milestone payments per program as well as royalties on sales of approved products.

“Merck is a world leader in solid-tumor cancer therapies and has a demonstrated history of delivering breakthrough treatment options for patients,” said Bill Haney, co-founder and CEO of Dragonfly Therapeutics. “We’re excited to work with Merck to accelerate bringing drug candidates developed using our innovative TriNKET™ technology platform to patients with a number of solid tumor malignancies.”

“Dragonfly’s technology platform offers an opportunity to harness the power of NK cell receptor engagement to develop novel therapeutics targeting solid tumor indications,” said Dr. Joe Miletich, Senior Vice President Discovery and Preclinical Development, Merck Research Laboratories. “We look forward to working with the Dragonfly team.”